Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Discovery Science Driving Clinical Breakthroughs For more information… Access the abstracts Session PO.ET03.05 – Reversal of Drug Resistance – […]
www.edisongroup.com
Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]
Read the interview
DIRECT DIRIGEANTS – EasyBourse A debate during which Onxeo’s CEO presents the company’s development strategy, activities, results and prospects. […]
Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Last day of trading on Nasdaq Copenhagen will be 11 December 2020 and the first day of trading on Nasdaq […]
November 9, 2020 Access management presentation Access live webcast replay
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]
CIC Market Solutions Forum Pour en savoir plus …
More information coming soon …
This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]
October 5-6, 2020 in Paris, France (virtual conference) This event includes conferences and meetings between innovative European companies in the […]
Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Watch the replay of the video conference of Judith Greciet, CEO, and Nicolas Fellmann, CFO, commenting on the half-yearly […]
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]
September 14-16, 2020 (virtual conference) Onxeo’s management team will present the Company on September 15 at 1:00 pm EDT (19:00 […]
Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Shareholders’ Combined General Meeting of May 29, 2020 in Camera Access the Managment Presentation to the General Meeting of […]
Extraordinary General Meeting of 19 June 2020 in camera on 2nd call The Extraordinary General Meeting was held on second […]
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Kepler Cheuvreux – Digital Life Science Day For more information, visit : www.keplercheuvreux.com Access the presentation from the […]
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
American Association for Cancer Research 2020 – Virtual Annual Meeting II The AACR Annual Meeting program covers the latest […]
(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]
PARP & DDR Inhibitors Summit 2020 The DNA Damage Response Therapeutics Summit brings together the leading pharma and biotech companies […]
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022 Paris […]
The Extraordinary General Meeting will be held on June 19, 2020 on the second call Paris (France), May 29, […]
Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]
Download management presentation
This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology $6.6m […]
The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]
BIO-Europe Spring [Virtual Conference] For more information…
Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Dowload the press release